Anbio Biotechnology (NNNN) financial statements
Anbio Biotechnology reported revenue of $9M in fiscal 2025, down 28.4% a year over 3 years.
Net income was $6M and the operating margin 66.7%, against 43.3% in 2022.
The diluted share count rose 43671922% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Anbio Biotechnology's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $24M | $7M | $8M | $9M |
| Cost of revenue | $11M | $3M | $2M | $1M |
| Gross profit | $13M | $3M | $6M | $8M |
| Research and development | $200,000 | $134,700 | $454,227 | $201,305 |
| Selling, general and admin | $2M | $1M | $3M | $2M |
| Operating income | $10M | $2M | $2M | $6M |
| Interest expense | $7,999 | — | — | — |
| Pre-tax income | $10M | $2M | $2M | $6M |
| Income tax | — | $0 | $0 | $0 |
| Net income | $10M | $2M | $2M | $6M |
| EPS (diluted) | $100,112.00 | $0.10 | $0.06 | $0.15 |
| Diluted shares | 0M | 21M | 42M | 44M |
| Gross margin | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
Balance sheet
Fiscal years, from Anbio Biotechnology's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $7M | $10M | $12M | $12M |
| Receivables | — | $2M | $1M | $4M |
| Total current assets | — | $16M | $19M | $30M |
| Total assets | — | $16M | $19M | $30M |
| Total current liabilities | — | $993,060 | $2M | $87,836 |
| Total liabilities | — | $993,060 | $2M | $87,836 |
| Shareholders' equity | $13M | $15M | $17M | $30M |
| Net debt | -$7M | -$10M | -$12M | -$8M |
Cash flow
Fiscal years, from Anbio Biotechnology's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | $4M | $898,367 | $2M | -$7M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NNNN.
Open NNNN in InvestinglyQuestions
What was Anbio Biotechnology's revenue in 2025?
$9M in fiscal 2025, from its 10-K filing.
From Anbio Biotechnology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.